Moberg Pharma以Lamisil品牌向Karo保健公司发放抗芬格尔药物Terclara许可证,供19个欧洲国家销售。 Moberg Pharma licenses its antifungal drug Terclara to Karo Healthcare for sale in 19 European countries under the Lamisil brand.

Moberg Pharma为19个欧洲国家,包括主要的欧盟国家和联合王国,向Karo保健机构发放了以Terclara销售的抗芬格尔药物MOB-015的许可证,以便商业化。 Moberg Pharma has licensed its antifungal drug MOB-015, marketed as Terclara, to Karo Healthcare for commercialization in 19 European countries, including major EU nations and the UK. Karo将处理Lamisil品牌的营销、分销和销售事宜,Moberg将获得特许权使用费和供应补偿。 Karo will handle marketing, distribution, and sales under the Lamisil brand, while Moberg will receive royalties and supply compensation. 交易的目的是将Terclara的市场存在扩大到瑞典和挪威之外,利用Karo的欧洲影响力。 The deal aims to expand Terclara’s market presence beyond Sweden and Norway, leveraging Karo’s European reach. 财务条款没有披露,也没有提供监管批准或启动的时间表。 Financial terms were not disclosed, and no timeline for regulatory approval or launch was provided. 正在对这一药物进行稀有疾病评估,伙伴关系的重点是加快患者获得创新治疗的机会。 The drug is being evaluated for rare diseases, with the partnership focused on accelerating patient access to innovative treatments.